Hepatobiliary manifestations occur quite frequently in patients suffering from chronic ulcerative colitis and Crohn's disease and carry with them considerable morbidity and mortality. Although the true incidence is difficult to determine, clinically significant hepatobiliary disease occurs in 5%-10% of patients. At the present moment, the aetiology and pathogenesis of inflammatory bowel disease and its systemic manifestations remains speculative. For those hepatobiliary manifestations that respond to therapy of the underlying bowel disease, medical and/or surgical therapy must be aggressively pursued. More urgent research is required towards understanding the underlying cause(s) of the primary bowel disease and its systemic manifestations in order to improve the overall management of this condition.
INTRODUCTION
Chronic ulcerative colitis (CUC) and Crohn's disease (CD), though chiefly effect the gastrointestinal tract, are frequently associated with a wide array of extraintestinal manifestations (EIM), the incidence of which varies between 25% and 36% [1] [2] [3] . Hepatobiliary manifestations are amongst the most common EIM associated with inflammatory bowel disease (IBD). They not only complicate the management of the primary disease but also contribute significantly to mortality and morbidity. Even before CUC was recognized as a clinical entity, fatty liver changes with diffuse colonic ulceration were described as early as 1874 by Thomas [4] which were confirmed by Lister in 1889 [5] who reported a patient with CUC and secondary diffuse hepatitis. Further evidence of association between CUC and hepatic involvement emerged from an autopsy study [6] . Although initial studies failed to show any association between CD and hepatobiliary disease, it soon became apparent that liver and biliary tract involvement occurs with equal frequency in patients with CD and CUC [7] .
Although the prevalence of hepatobiliary disease in patients with IBD varies widely in different series from 2%-95%, clinically significant liver disease occurs in only 5%-10% of patients [8] (Tab. I). Such a discrepancy between the various series occurs because of a number of factors which include (a) on how aggressively diagnostic studies are pursued; (b) the number of patients included with mild, moderate and severe disease; (c) whether the disease was active or in remission and (d) the type of bowel involvement i.e., extensive or limited. There is no consistent temporal relationship between the onset of symptoms and hepatobiliary abnormalities [7] . On average, CUC is present for approximately 8 years before the hepatic abnormalities become apparent [7] . 
FATTY LIVER (HEPATIC STEATOSIS)
Fatty liver occurs in 15%-80% of patients with IBD [9] . Patients with severe colitis, fulminant first attack of colitis and those requiring colectomy over the age of 50 have the highest risk of developing this condition [8] . The [2, 8, [11] [12] [13] . It occurs more frequently in CD than in CUC, and is perhaps more a secondary complication rather than a systemic manifestation. In CD, there is a positive correlation between stone formation and location, extent, and duration of ileal involvement as well as ileal resection and increased patient age [2, [13] [14] [15] . For CUC, total colitis extending to the caecum poses the greatest risk for gallstones [19] . Since then this relationship between biliary tract tumors and CUC has been well established. The reported incidence of cholangiocarcinoma in patients with IBD is between 0.4% 1.4%, which is 10 100 times greater than reported for the general population [9, [20] [21] [22] [23] [24] .
On the other hand, the incidence of CUC in patients with bile duct cancer is between 6% and 14% [24] . It is more common in men and occurs in the fourth and fifth decades, about 20 years earlier than in the general population [8, 10, 14] . It occurs predominantly in patients with CUC, but has also been reported in patients with CD. Most cholangiocarcinomas develop in patients with preexisting PSC [25] . The greatest risk appears to be for those CUC patients with pancolitis and for those with an average duration of 15 years of disease [9] . There is no apparent relationship between the development of cholangiocarcinoma and the activity of bowel disease as it may develop during prolonged remission and even following proctocolectomy [21, 22, 26, 27] . [8] . Similarly the results of orthotopic liver transplantation has been disappointing due to early recurrences [30] . Fibrolamellar hepatocellular carcinoma has recently been diagnosed in two patients with CUC and PSC [31, 32] . Both of these patients were free of cirrhosis. One of these patients received liver transplantation but died of tumor recurrence [32] .
LIVER CIRRHOSIS
Cryptogenic liver cirrhosis occurs in approximately 1-5% of patients with hepatic abnormalities and IBD [33, 34] . It is more frequently seen in extensive ulcerative colitis or Crohn's colitis as compared to Crohn's ileitis. Autoimmune Chronic Active Hepatitis (AICAH), pericholangitis and PSC are important risk factors [9] . In some patients who have received multiple blood transfusions, hepatitis C may be a causative agent. The treatment of choice for end stage liver disease is liver transplantation. Central portosystemic shunts must be avoided as not only do they increase perioperative mortality rates but they also make liver transplantation technically more challenging [8] . Patients [50] . However, when CD involves the large bowel, the incidence of PSC increases to 9%, a rate similar to CUC [51] . On the other hand between 54% and 100% of PSC patients have IBD [47, [52] [53] [54] [55] [56] .
Currently the etiopathogenesis of both PSC and IBD remains speculative. Present evidence however suggests that PSC is an autoimmune disorder, where immunologic factors triggered by a virus or bacteria in genetically susceptible individuals are thought to damage bile duct epithelial cells [57] . Other factors that have been implicated in the etiology of PSC include environmental toxins, hepatic copper, viral infections (hepatitis A,B,C,D, cytomegalovirus, and reovirus), portal bacteremia, absorbed colonic toxins, toxic bile acids, genetic predisposition (HLA-B8, HLA-DR2, HLA-DR3 and HLADRw52A), ischemic arteriolar injury and altered cellular and humoral immunological responses [47, [58] [59] [60] [61] [62] [63] [64] [65] [66] .
There is no relationship between PSC and the onset, duration, activity, or extent of CUC [2, [67] [68] [69] . It can even present years after proctocolectomy [67] [68] [69] [70] [33, 78] . It is now believed that pericholangitis represents a continuum in the spectrum of PSC [79] . The majority of cases resolve with residual mild periductal fibrosis, some may progress to a chronic phase or to PSC or to cirrhosis [7, 79, 80] 
